News
Why Amedisys Shares Slumped 24.6% in July
Amedisys Inc. (NASDAQ: AMED) shares lost nearly 25% of their value last month, according to S&P Global Market Intelligence. The drop was caused by word that the the federal government's Centers for
Why Tenet Healthcare Shares Dropped 14.4% Today
After reporting second-quarter earnings and offering up guidance for 2017, shares of Tenet Healthcare (NYSE: THC) have fallen 14.6% as of 2:30 p.m. EDT on Tuesday.Tenet Healthcare's year-over-year
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
Investors saw the end of a historic bullish streak for stocks on Tuesday, as the Dow Jones Industrials failed in their bid for a 10th straight day of record-setting gains. Instead, major benchmarks
MyoKardia Inc. Is on the Rise Again Today -- Here's Why
After a monster run-up on Monday, MyoKardia Inc. (NASDAQ: MYOK) climbed another 145.9% as of 3:30 p.m. during Tuesday's session. It seems investors still giddy about positive clinical trial data
Why FibroGen Inc Skyrocketed Higher Today
FibroGen (NASDAQ: FGEN) is up nearly 50% at 1:10 p.m. Tuesday after releasing positive data from its phase 2 trial testing pamrevlumab in patients with a lung disease called idiopathic pulmonary
Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10%
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's traditionally grown through acquisitions and price hikes over the years, surged as much as 10% during Tuesday's trading
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for....
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for several of
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
When GW Pharmaceuticals (NASDAQ: GWPH) announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. There were at least
Emergent Biosolutions Inc Diversifies Its Revenue
One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1
The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)
Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.Valeant Pharmaceuticals
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance
Why GW Pharmaceuticals Could Be a Gold Mine for Growth Investors
You've probably heard of the great California gold rush of the mid-19th century. Today, many are flocking to what has been called the "green rush" -- a major wave of money flowing into the marijuana
Insulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7%
Insulet (NASDAQ: PODD) reported second-quarter 2017 earnings after the market closed on Thursday. The drug-delivery company, which is a leader in tubeless insulin pump technology with its Omnipod
Down 9.8%: Is Masimo Corporation Stock a Contrarian Buy?
Masimo Corporation (NASDAQ: MASI), a mid-cap medical technology company, reported stronger-than-expected second-quarter results after the bell Wednesday, but investors still decided to hit the exits
Here's What's Pressuring Glaukos Corp Stock Today
Shares of Glaukos Corp (NYSE: GKOS), a medical technology company focused on glaucoma treatment, were down about 9.8% as of 11:46 a.m. on Thursday in response to a second-quarter earnings report
Genomic Health, Inc.: Still Waiting for Reimbursement
Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net
Globus Medical Enjoys Another Solid Quarter Thanks to International Sales Growth
So far, 2017 is shaping up to be the best year for Globus Medical (NYSE: GMED) shareholders in quite a while. The musculoskeletal implant manufacturer posted great numbers for the first quarter
3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
Novocure (NASDAQ: NVCR) is the company behind TTFields, a revolutionary new and nontoxic treatment for glioblastoma that uses low-intensity, alternating electrical fields to impede cancerous cell
Here's Why Spark Therapeutics Inc. Is Soaring Today
After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on
Here's Why Amarin Corporation plc Is on the Rise Today
Shares of Amarin Corporation plc (NASDAQ: AMRN), a cardiovascular health-focused biotech, popped 12.9% higher this morning after reporting second-quarter earnings. Investors cheered the
It's Time for Investors to Get Over the Biggest Misconception About Valeant Pharmaceuticals
Nearly two years ago to the day, Valeant Pharmaceuticals (NYSE: VRX) would hit almost $264 a share in intraday trading and support a roughly $90 billion market valuation. The embattled drugmaker has